Helicobacter pylori eradication therapy Helicobacter pylori
Conditions
Interventions
Vonoprazan-amoxicillin-rifabutin treatment: Vonoprazan 20mg twice a day (40mg/day), amoxicillin 750mg 12 times a day (1500mg/day), rifabutin 150mg twice a day (300mg/day), all three drugs administered
Sponsors
Sue Soichiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age 18 years or older at the time of enrollment (2) Patients with confirmed Helicobacter pylori infection (3) Patients who have failed first-line eradication therapy (PPI or PCAB + amoxicillin + clasithromycin for 1 week) or second-line eradication therapy (PPI or PCAB + amoxicillin + metronidazole for 1 week) approved for insurance coverage in Japan (4) Patients who have given consent to participate in this clinical study
Exclusion criteria
Exclusion criteria: (1) Pregnant or possibly pregnant patients (2) Breastfeeding patients (3) Patients with a history of allergies to the test drug (4) Patients taking drugs that are contraindicated for use with the study drug. (5) Patients with other serious diseases (liver failure, renal failure, heart failure, etc.) Liver function is based on a total bilirubin level of 1.5 mg/dL, and renal function is based on a creatinine level of 1.2 mg/dL. (6) Patients who are otherwise deemed unsuitable as subjects by the principal investigator (subinvestigator)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment compliance, Safety | — |
Contacts
Public ContactSoichiro Sue
Yokohama City University Hospital
Outcome results
None listed